

May 17, 2001

For Further Information
 Yukio Shimonaka, Director
 Corporate Communications
 TEL. 06-6206-7857
 FAX. 06-6206-5016

Fujisawa Announces Financial Results for FY 2001

Japan, May 17, 2001 – Fujisawa Pharmaceutical Co., Ltd. today announced its financial results for fiscal year 2001 ended March 2001 (FY 2001). This is an extract of certain key information from the announcements. All information in this release are on a consolidated basis unless otherwise specified and some figures are re-classified from original announcement in Japanese for good uniformity to the annual report to be published in early August this year. The U.S. dollar amounts in this announcement represent, for convenience only, translations of Japanese yen at the rate of 124 yen per one U.S. dollar

Financial Highlights

| | FY2000 | FY2001 | | | FY2002 Forecast | |
|------------------------------|----------------|----------------|-----------------|---------------|--------------------|-------------|
| | Million Yen | Million Yen | Million US\$ | % *1 | Million Yen | % *1 |
| Net sales | 289,142 | 297,516 | 2,399 | 2.9 | 326,000 | 9.6 |
| Operating income | 34,843 | 33,605 | 271 | (3.6) | 38,500 | 14.6 |
| Recurring income | 35,682 | 35,727 | 288 | 0.1 | 41,000 | 14.8 |
| Net income | 22,906 | 20,528 | 166 | (10.4) | 22,500 | 9.6 |
| Shareholders equity | 262,968 | 278,581 | 2,247 | 5.9 | | |
| Per share profit(yen) | 71.09 | 63.62 | US\$0.51 | (10.5) | | |
| Total assets | 435,551 | 462,324 | 3,728 | 6.1 | | |
| R&D expenses | 45,565 | 52,015 | 419 | 14.2 | 58,000 | 11.5 |

*1: Changes from previous year in %.

Results of FY2001

Net sales

Net sales recorded the historical high with **297,516 million yen** (US \$ **2,399 million**) up 2.9% over FY 2000.

- Sales in Japan increased by 0.5% to 205,150 million yen (US \$ **1,654million**). Ethical pharmaceuticals, the Company's main business showed a 1.5% increase over the year earlier led by the anti-depressant *Luvox*, the immunosuppressant *Prograf*, and *Protopic* for the treatment of atopic

dermatitis. A series of newly launched products in FY 2001, *Dovonex* for psoriasis, *Colonel* for irritable bowel syndrome, the hypnotic *Myslee* and the antipsychotic *Seroquel* also contributed to the sales growth. On the other hand, the sales of the cephalosporin antibiotic *Cefzon* and the anti-glaucoma *Rescula* decreased. Home care business also posted brisk sales while export business decreased due to keen competition on pharmaceutical bulk business of antibiotics.

- North America recorded double-digit growth of 18.2 % with **58,094 million yen (US \$ 469 million)**. Sales of Fujisawa Healthcare, Inc. jumped up 25% to US \$ 509 million on a local currency basis led by *Prograf*, the physiological stress imaging agent *Adenoscan* and the injectable antifungal *AmBisome*.
- The sales in Europe decreased by 6.8 % to **29,752 million yen (US \$ 240 million)** from the previous year due to much weaker Euro against Japanese yen. On local currency basis, the sales increase of Fujisawa GmbH by Euro 34 million to Euro 142 million more than offset the slight sales decrease of Klinge Pharma GmbH by Euro 5 million to Euro 146 million
- In the other region, the sales increased by 14.7 % to **4,518 million yen (US \$ 36 million)**.

The ratio of the overseas sales (the parent's export sales and royalty income from overseas and the sales of the foreign consolidated subsidiaries, to third parties, respectively) slightly increased to 36.3 % with **108,080 million yen (US \$ 872 million)**, compared with 35.3% of the year earlier.

Operating income

Gross profit increased due to the increase of net sales despite of lowered gross margin by changes in product mix. As Fujisawa invested **52,015 million yen (US \$ 419 million)**, or 17.5% of net sales into research and development expenses, Operating income decreased by 3.6 % to **33,605 million yen (US \$ 271 million)** over FY 2000. By location, operating on incomes in North America and Europe increased while Japan slated the decrease.

Recurring income

Despite of lowered Operating income, Recurring income recorded the historical high with **35,727 million (US \$ 288 million)**, up 0.1% over the year earlier. The increases in net surplus in non-operating income and expenses at the parent company and at Fujisawa Healthcare, Inc. exceeded decrease of Operating income.

Net income

- Net of Extraordinary Gain and Loss was surplus of **462 million yen (US \$ 4 million)**, decrease of **410 million yen (US \$ 3 million)** from the year earlier. Further, taxes increased by **1,994 million (US \$ 16 million)** yen. As a result, Net income decreased to **20,528 million yen (US \$ 166 million)**, down 10.4 % from the year earlier.

Cash flow

- Cash flow from operating activities recorded increase of 33,007 million yen (US \$ 266 million) with

Net income before adjustments for taxes of **36,190 million yen (US \$ 292 million)** as well as depreciation and amortization of **16,102 million yen (US \$ 130 million)**.

- Cash flow from investing activities amounted to 23,731 million yen (US \$ 191 million). Capital expenditures totaled **20,586 million yen (US \$ 166 million)**, which were used mainly for the construction of new formulation facilities for Protopic, and new manufacturing facilities for tacrolimus bulk chemicals, both in the Toyama plant, and new manufacturing facilities for micafungin, an injectable antifungal agent, in Nagoya, Toyama and Takaoka plants
- Cash flow from financing activities recorded decrease of 12,970 million yen (US \$ 105 million). Short-term borrowings of 8,681 million yen (US\$ 70 million) were repaid, which reflected the Company's policy to reduce outstanding debts in order to improve assets efficiency.
- Cash and cash equivalent at the end of the period was 32,023 million yen (US \$ 258 million), decrease of 2,975 million yen (US \$ 24 million) from the beginning of the period.

Appendix

| I. Financial Information | Page |
|--|------|
| (1) Balance Sheets | 4 |
| (2) Statements of Income | 5 |
| (3) Statements of Cash Flows | 6 |
| (4) Currency Conversion Rates | 7 |
| | |
| II. Segment Information | |
| (1) By Business Lines | 7 |
| (2) By Business Lines (details – Sales only) | 8 |
| (3) By Geographical Areas | 8 |
| (4) Overseas Sales | 9 |
| | |
| III. Supplemental Information | |
| (1) Prograf Sales | 9 |
| (2) Sales of Ethical Pharmaceuticals by Therapeutic Category | 9 |
| (3) Sales of Top 15 Products | 10 |
| (4) Products Under Clinical Development | 11 |

I. Financial Information

(1) Balance Sheets

| | March 31, 2000 | March 31, 2001 | | Change (b-a) |
|---|--------------------|--------------------|-----------------|-----------------|
| Assets | Million Yen (a) | Million Yen (b) | Million US\$ | Million Yen |
| I. Current assets | 241,713 | 197,054 | 1,589 | (44,659) |
| 1. Cash and cash equivalents | 15,846 | 13,774 | 111 | |
| 2. Marketable securities and short term-investments | 87,396 | 30,522 | 246 | |
| 3. Accounts receivable | 77,914 | 81,993 | 661 | |
| 4. Inventories | 38,934 | 43,159 | 348 | |
| 5. Deferred taxes (current) | 8,960 | 9,725 | 78 | |
| 6. Prepaid expenses and other current assets | 12,662 | 17,879 | 144 | |
| II. Fixed assets | 179,975 | 265,269 | 2,139 | 85,294 |
| (1)Property, plant and equipment | 90,898 | 103,613 | 836 | 12,715 |
| (2)Investments and other assets | 89,076 | 161,655 | 1,304 | 72,579 |
| 1. Goodwill and proprietary technology | 17,793 | 19,042 | 154 | |
| 2. Excess of cost over net assets acquired-net | 981 | 773 | 6 | |
| 3. Investments in securities | 32,396 | 111,462 | 899 | |
| 4. Deferred taxes (fixed) | 20,202 | 13,285 | 107 | |
| 5. Other assets | 17,702 | 17,091 | 138 | |
| III. Translation adjustments | 13,862 | - | - | (13,862) |
| Total assets | 435,551 | 462,324 | 3,728 | 26,773 |
| Liabilities | 170,439 | 181,795 | 1,466 | 11,356 |
| I. Current liabilities | 79,564 | 116,279 | 938 | 36,715 |
| 1. Accounts payables | 42,230 | 48,888 | 394 | |
| 2. Short-term debt | 13,918 | 31,718 | 256 | |
| 3. Accrued liabilities | 11,134 | 19,285 | 156 | |
| 4. Others | 12,281 | 16,384 | 132 | |
| II. Long-term liabilities | 90,874 | 65,515 | 528 | (25,359) |
| 1. Long-term debt | 41,865 | 16,621 | 134 | |
| 2. Accrued severance indemnities | 46,861 | 45,713 | 369 | |
| 3. Other long-term liabilities | 2,146 | 3,180 | 26 | |
| Minority interest In consolidated subsidiaries | 2,144 | 1,948 | 16 | (196) |
| Shareholders' equity | 262,968 | 278,581 | 2,247 | 15,613 |
| I. Common stock, (50 yen par value) | 31,819 | 32,045 | 258 | 226 |
| II. Capital surplus | 50,465 | 50,690 | 409 | 225 |
| III. Retained earnings, others | 180,684 | 197,505 | 1593 | 16,821 |
| . Unrealized gain (loss) on marketable securities | - | 8,389 | 68 | 8,389 |
| . Translation adjustments | - | (10,048) | (81) | (10,048) |
| Liabilities and Shareholders' equity total | 435,551 | 462,324 | 3,728 | 26,773 |

(2) Statements of Income

| | FY2000 | FY2001 | | Change (b-a) |
|---|--------------------|--------------------|-----------------|-----------------|
| | Million Yen (a) | Million Yen (b) | Million US\$ | Million Yen |
| I. Net sales | 289,142 | 297,516 | 2,399 | 8,374 |
| II. Cost of Sales | 102,088 | 108,424 | 874 | 6,336 |
| Gross profit | 187,052 | 189,091 | 1,525 | 2,039 |
| III. Selling, general and Administrative expenses (including amortization of excess of cost over net assets acquired) | 106,644 | 103,471 | 834 | (3,173) |
| IV. R&D expenses | 45,565 | 52,015 | 419 | 6,450 |
| Operating income | 34,843 | 33,605 | 271 | (1,238) |
| V. Non-operating income | 8,868 | 9,947 | 80 | 1,079 |
| 1. Interest income | 2,301 | 2,696 | 22 | |
| 2. Dividend | 681 | 335 | 3 | |
| 3. Gain on sale of marketable securities | 1,251 | 1,113 | 9 | |
| 4. Operating profit of money trust | 1,364 | - | - | |
| 5. Foreign exchange gain | - | 1,030 | 8 | |
| 6. Others | 3,269 | 4,771 | 38 | |
| VI. Non-operating expenses | 8,029 | 7,825 | 63 | (204) |
| 1. Interest expenses | 2,977 | 2,059 | 17 | |
| 2. Loss on sale of marketable securities | 833 | 185 | 1 | |
| 3. Others | 4,218 | 5,580 | 45 | |
| Recurring income | 35,682 | 35,727 | 288 | 45 |
| VII. Extraordinary gain | 5,262 | 1,340 | 11 | (3,922) |
| 1. Recovery from the settlement of pending litigations | 4,105 | - | - | |
| 2. Gain on sale of investment securities | 1,157 | 1,242 | 10 | |
| 3. Profit on sale of fixed asset and others | - | 97 | 1 | |
| VIII. Extraordinary loss | 4,390 | 878 | 7 | (3,512) |
| 1. Amortization of the unfunded amounts of retirement benefit obligation | 2,562 | - | - | |
| 2. Foreign exchange loss on long-term debt | 1,827 | - | - | |
| 3. Write down of investment securities | - | 481 | 4 | |
| 4. Write down of golf club membership | - | 396 | 3 | |
| Income before income taxes | 36,553 | 36,190 | 292 | (363) |
| IX. Income taxes | 13,495 | 15,489 | 125 | 1,994 |
| XI. Minority interest in consolidated subsidiaries | 151 | 171 | 1 | 20 |
| Net income | 22,906 | 20,528 | 166 | (2,378) |

(3) Statements of Cash Flows

| | FY2000 | FY2001 | | Change (b-a) |
|---|--------------------|--------------------|-----------------|-----------------|
| | Million Yen (a) | Million Yen (b) | Million US\$ | Million Yen |
| Net income before adjustments for tax | 36,553 | 36,190 | 292 | (363) |
| Depreciation and amortization | 15,580 | 16,102 | 130 | 522 |
| Provision for accrued severance indemnities, less payments | 672 | (690) | (6) | (1,362) |
| Interests and dividend received | (1,888) | (3,031) | (24) | (1,143) |
| Interests paid | 2,268 | 2,059 | 17 | (209) |
| Foreign exchange gain | - | (973) | (8) | (973) |
| Foreign exchange loss | 2,854 | - | - | (2,854) |
| Write down of investment securities | - | 481 | 4 | 481 |
| Write down of golf club membership | - | 396 | 3 | 396 |
| Profit on sale of investment securities | - | (1,242) | (10) | (1242) |
| (Increase) decrease in trade receivable | 4,525 | (3,996) | (32) | (8,521) |
| (Increase) decrease in inventory | (4,272) | (4,225) | (34) | 47 |
| Increase (decrease) in trade payable | (2,753) | 81 | 1 | 2,834 |
| Others | 322 | (2,214) | (18) | (2,536) |
| Sub total | 53,861 | 38,938 | 314 | (14,923) |
| Interests and dividends received (real amount) | 2,103 | 3,105 | 25 | 1,002 |
| Interests paid (real amount) | (2,472) | (2,192) | (18) | 280 |
| Amount paid for income tax, etc. | (5,870) | (7,982) | (64) | (2,112) |
| Refunded income tax, etc. | 8,305 | 1,138 | 9 | (7,167) |
| Cash flow from operating activities | 55,926 | 33,007 | 266 | (22,919) |
| Acquisition of fixed assets | (19,779) | (20,586) | (166) | (807) |
| (Increase) decrease in marketable securities | (8,811) | (1,133) | (9) | 7,678 |
| Sale of investment securities | 2,050 | 49,188 | 397 | 47,138 |
| Acquisition of investment securities | (952) | (56,448) | (455) | (55,496) |
| Others | 2,353 | 5,248 | 42 | 2,895 |
| Cash flow from investing activities | (25,139) | (23,731) | (191) | 1,408 |
| Net borrowings (repayments) of short-term borrowings | (26,724) | (8,681) | (70) | 18,043 |
| Borrowings of long-term debt | 4,693 | - | - | (4,693) |
| Repayments of long-term debt | (11,956) | (55) | (0) | 11,901 |
| Dividends paid | (3,623) | (4,193) | (34) | (570) |
| Payments for dividends to minority shareholders | (73) | (53) | (0) | 20 |
| Others | (0) | 13 | 0 | 13 |
| Cash flow from financing activities | (37,683) | (12,970) | (105) | 24,713 |
| Effect of exchange rate changes on cash and cash equivalents | (1,151) | 741 | 6 | 1,892 |
| Increase of cash and cash equivalents for newly consolidated subsidiaries | 1,264 | - | - | (1,264) |
| Net increase (decrease) in cash and cash equivalents | (6,784) | (2,975) | (24) | 3,809 |
| Cash and cash equivalents at beginning of year | 41,782 | 34,998 | 282 | (6,784) |
| Cash and cash equivalents at end of year | 34,998 | 32,023 | 258 | (2,975) |

(4) Currency Conversion Rates

| | FY2000 | | FY2001 | | |
|---------------------------|-----------|--------|-----------|--------|--------|
| | Ave.* | End** | Ave.* | End** | |
| For overseas subsidiaries | Jan.-Dec. | Dec. | Jan.-Dec. | Dec. | |
| | US\$ | 113.49 | 102.40 | 108.42 | 114.75 |
| | EURO | 120.28 | 103.01 | 99.56 | 106.57 |
| | DM | 61.50 | 52.67 | 50.91 | 54.49 |
| For parent's business | Apr.-Mar. | Mar. | Apr.-Mar. | Mar. | |
| | US\$ | 110.70 | 106.15 | 111.19 | 123.90 |
| | EURO | 113.53 | 101.85 | 100.45 | 109.28 |
| | DM | 58.05 | 52.08 | 51.36 | 55.87 |

FY2002 forecasts are based on 115 yen for US\$ and 100 yen for EURO

* :Average during the period. (mainly for the translation of statement of income)

** :At end of the period. (mainly for the translation of balance sheets)

II. Segment Information

(1) By Business Lines

| | FY2001 | | | | |
|--|-----------------|------------|---------------|---------------------------|---------------|
| | Pharmaceuticals | Others | Total | Eliminations or corporate | Consolidated |
| I. Sales and operating income | | | | | |
| (1)Net sales to unrelated entities | 263,020 | 34,496 | 297,516 | - | 297,516 |
| (2)Transfers between business segments | 22 | 5,157 | 5,180 | (5,180) | - |
| Total | 263,042 | 39,654 | 302,696 | (5,180) | 297,516 |
| Operating expenses | 229,555 | 39,449 | 269,005 | (5,094) | 263,910 |
| Operating income | 33,486 | 204 | 33,691 | (85) | 33,605 |
| II. Assets, depreciation and capital expenses | | | | | |
| Assets | 324,866 | 39,125 | 363,991 | 98,332 | 462,324 |
| Depreciation and amortization | 13,544 | 2,558 | 16,103 | - | 16,103 |
| Capital expenditure | 27,568 | 3,054 | 30,623 | - | 30,623 |

| | FY2000 | | | | |
|--|-----------------|----------------|---------------|---------------------------|---------------|
| | Pharmaceuticals | Others | Total | Eliminations or corporate | Consolidated |
| I. Sales and operating earning | | | | | |
| (1)Net sales to unrelated entities | 255,450 | 33,691 | 289,142 | - | 289,142 |
| (2)Transfers between business segments | 13 | 4,156 | 4,170 | (4,170) | - |
| Total | 255,464 | 37,848 | 293,312 | (4,170) | 289,142 |
| Operating expenses | 218,396 | 39,789 | 258,185 | (3,887) | 254,298 |
| Operating income | 37,067 | (1,941) | 35,126 | (283) | 34,843 |
| II. Assets, depreciation and capital expenses | | | | | |
| Assets | 292,558 | 37,315 | 329,874 | 105,677 | 435,551 |
| Depreciation and amortization | 13,063 | 2,516 | 15,580 | - | 15,580 |
| Capital expenditure | 19,938 | 2,248 | 22,186 | - | 22,186 |

(2) By Business Lines (details – sales only)

| | FY2000 | | FY2001 | |
|--------------------------------------|----------------|--------------|----------------|--------------|
| | Million yen | Ratio % | Million yen | Ratio % |
| Pharmaceutical business total | 255,450 | 88.3 | 263,020 | 88.4 |
| Ethical Pharmaceutical | 240,028 | 83.0 | 248,324 | 83.5 |
| OTC drugs | 15,421 | 5.3 | 14,695 | 4.9 |
| Other business total | 33,691 | 11.7 | 34,496 | 11.6 |
| Medical supplies and systems | 2,944 | 1.0 | 2,984 | 1.0 |
| Chemicals and animal health products | 22,468 | 7.8 | 22,083 | 7.4 |
| Home care business | 4,358 | 1.5 | 5,652 | 1.9 |
| Others | 3,920 | 1.4 | 3,776 | 1.3 |
| Grand total | 289,142 | 100.0 | 297,516 | 100.0 |

(3) By Geographical Areas

| | FY2001 | | | | | | |
|--|----------------|---------------|---------------|--------------|----------------|---------------------------|----------------|
| | Japan | North America | Europe | Others | Total | Eliminations or Corporate | Consolidated |
| I. Sales and operating earning | | | | | | | |
| (1) Net sales to unrelated entities | 205,150 | 58,094 | 29,752 | 4,518 | 297,516 | - | 297,516 |
| (2) Transfers between geographic areas | 18,297 | 3,447 | 6,728 | 21 | 28,495 | (28,495) | - |
| Total | 223,448 | 61,542 | 36,481 | 4,540 | 326,011 | (28,495) | 297,516 |
| Operating expenses | 205,895 | 47,967 | 32,899 | 4,110 | 290,873 | (26,962) | 263,910 |
| Operating income | 17,552 | 13,574 | 3,581 | 429 | 35,138 | (1,532) | 33,605 |
| II. Assets | 281,043 | 58,961 | 39,759 | 4,169 | 383,933 | 78,391 | 462,324 |

| | FY2000 | | | | | | |
|--|----------------|---------------|---------------|--------------|----------------|---------------------------|----------------|
| | Japan | North America | Europe | Others | Total | Eliminations or Corporate | Consolidated |
| I. Sales and operating earning | | | | | | | |
| (1) Net sales to unrelated entities | 204,137 | 49,144 | 31,919 | 3,939 | 289,142 | - | 289,142 |
| (2) Transfers between geographic areas | 13,404 | 4,820 | 5,343 | 17 | 23,586 | (23,586) | - |
| Total | 217,542 | 53,965 | 37,263 | 3,957 | 312,728 | (23,586) | 289,142 |
| Operating expenses | 197,243 | 42,222 | 34,315 | 3,672 | 277,453 | (23,154) | 254,298 |
| Operating income | 20,298 | 11,743 | 2,947 | 285 | 35,275 | (431) | 34,843 |
| II. Assets | 254,211 | 49,498 | 39,842 | 3,636 | 347,189 | 88,361 | 435,551 |

(4) Overseas Sales

| | FY2001 (in million yen) | | | |
|------------------------|-------------------------|--------|--------|----------------|
| | North America | Europe | Others | Total Overseas |
| I. Overseas sales(a) | 63,255 | 34,187 | 10,636 | 108,080 |
| II. Net sales(b) | 297,516 | | | |
| III. Ratio(a / b) in % | 21.3 | 11.5 | 3.6 | 36.3 |

| | FY2000 (in million yen) | | | |
|------------------------|-------------------------|--------|--------|----------------|
| | North America | Europe | Others | Total Overseas |
| I. Overseas sales(a) | 55,598 | 36,411 | 10,184 | 102,195 |
| II. Net sales(b) | 289,142 | | | |
| III. Ratio(a / b) in % | 19.2 | 12.6 | 3.5 | 35.3 |

III. Supplemental Information

(1) Prograf Sales (Upper center or center : billion yen, Lower right : million \$, Euro or DM)

| | FY1999 | FY2000 | FY2001 | FY2002 forecast |
|---------------|-----------------------|----------------------------------|-------------------|-------------------|
| Japan | 3.4 | 4.5 | 5.6 | 6.0 |
| North America | 18.2 \$139 | 22.6 \$199 | 28.5 \$263 | 37.1 \$323 |
| Europe | 11.5 (DM141.5+\$7) | 13.9 (Euro114) (DM211+\$8) | 15.2 (Euro153) | 18.7 (Euro187) |
| Others | 0.2 | 0.8 | 1.3 | 1.5 |
| Total | 33.3 | 41.8 | 50.6 | 63.3 |

(2) Sales of Ethical Pharmaceuticals by Therapeutic Category

| Consolidated | FY2000 | | FY2001 | | |
|---|-------------|------------|-------------|--------------|------------|
| | Million yen | % to total | Million yen | Million US\$ | % to total |
| Nervous system and sensory organs drugs | 33,233 | 13.8 | 33,334 | 269 | 13.4 |
| Cardiovascular and respiratory drugs | 42,379 | 17.7 | 41,854 | 338 | 16.9 |
| Digestive system drugs | 4,285 | 1.8 | 5,366 | 43 | 2.2 |
| Metabolic drugs | 42,230 | 17.6 | 51,354 | 414 | 20.7 |
| Anti-allergy drugs | 15,639 | 6.5 | 16,130 | 130 | 6.5 |
| Antibiotics and biological preparations | 78,117 | 32.5 | 75,921 | 612 | 30.6 |
| Others | 11,299 | 4.7 | 12,712 | 103 | 5.1 |
| Process Fees | 8,321 | 3.5 | 7,815 | 63 | 3.1 |
| Royalty Income | 4,521 | 1.9 | 3,834 | 31 | 1.5 |
| Total | 240,028 | 100.0 | 248,324 | 2,003 | 100.0 |

(3) Sales of Top 15 Products

| Consolidated | | Billion yen | | | Product category |
|-------------------------------|--------------------------|-------------------|-------------------|--------------------|--|
| | | FY2000 Results | FY2001 Results | FY2002 Forecast | |
| Product Name | Generic Name | | | | |
| 1. Prograf | Tacrolimus | 41.8 | 50.6 | 63.3 | Immunosuppressant |
| 2. Cefzon | Cefdinir | 33.9 | 29.1 | 30.0 | Oral cephalosporin |
| 3. Intal | Sodium cromoglycate | 15.7 | 16.0 | 14.1 | Anti-asthmatic and anti-allergic |
| 4. Nivadil | Nilvadipine | 15.4 | 14.2 | 14.4 | Anti-hypertensive and cerebrocirculation improving |
| 5. Adenoscan | Adenosine | 11.1 | 13.1 | 15.9 | Physiological stress imaging agent |
| 6. Cefamezin | Cefazolin | 13.0 | 11.8 | 10.6 | Injectable cephalosporin |
| 7. Cefspan | Cefixime | 10.0 | 9.7 | 9.4 | Oral cephalosporin |
| 8. Dogmatyl | sulpiride | 8.4 | 8.6 | 8.4 | Anti-ulcer and neuroleptic |
| 9. Rescula | Isopropyl unoprostone | 10.0 | 7.7 | 8.0 | Antiglaucoma |
| 10. AmBisome | Liposomal amphotericin B | 5.9 | 7.7 | 9.8 | Antifungal |
| 11. Luvox | Fluvoxamine maleate | 4.2 | 6.3 | 8.0 | Antidepressant |
| 12. Vaccines | - | 3.6 | 4.9 | 4.5 | |
| 13. Gramalil | Tiapride | 3.9 | 4.0 | 4.0 | Psychotics |
| 14. Cibenol | Cibenzoline | 3.4 | 3.8 | 4.0 | Antiarrhythmia |
| 15. Bolheal | Tacrolimus- | 3.8 | 3.7 | 3.6 | Fibrin glue |
| Protopic | Zolpidem | 0.4 | 1.3 | 7.9 | For atopic dermatitis |
| Myslee | - | - | 1.2 | 6.0 | Hypnotic |
| Currency conversion rate used | | 113.49 | 108.42 | 115.00 | (yen/US\$) |

(4) Products Under Clinical Development

May 17, 2001

| Product Name | Generic Name | Product Category | Stage In Japan | Remarks |
|--------------|--------------------|---|--------------------|---|
| Prograf | Tacrolimus (FK506) | Immunosuppressant (suppression of organ rejection in heart, lung, pancreas and small intestine transplant) | SNDA Filed ('00/2) | new indication |
| Prograf | Tacrolimus (FK506) | granular formulation for suppression of organ rejection in heart, lung, pancreas and small intestine transplant | SNDA Filed ('01/4) | Additional formulation |
| Prograf | Tacrolimus (FK506) | granular formulation for myasthenia gravis | SNDA Filed ('01/4) | Additional formulation |
| | Micafungin (FK463) | Antifungal (deep-seated fungal infection) | To be filed | Phase 3 in USA & Europe |
| | Zenarestat (FK366) | aldose reductase inhibitor(ARI) (diabetic neuropathy) | Phase 3 | Suspended in USA & Europe |
| Prograf | Tacrolimus (FK506) | Immunosuppressant (chronic rheumatoid arthritis) | Phase 3 | new indication Phase 3 in USA Phase 2 in Europe |
| Protopic | Tacrolimus (FK506) | Immunosuppressant (atopic dermatitis ointment for pediatric use) | Phase 3 | new indication NDA Filed in Europe (00/8) |
| ReoPro | Abciximab | Monoclonal antibody to GP b/ a receptors (prevention of cardiac ischemic complications after PTCA) | Phase 2 | Licensed from Centocor |
| | (FK960) | Antidementia (alzheimer's disease) | Phase 2 | Phase 2 in USA |
| | (FK317) | Anticancer antibiotic (solid cancer) | Phase 2 | Phase 1 in USA |
| | (FK614) | Insulin sensitizer (non-insulin dependent diabetes mellitus(NIDDM)) | Phase 2 | Phase 2 in USA |
| Prograf | Tacrolimus (FK506) | Immunosuppressant (lupus nephritis) | Phase 2 | new indication |
| | Tacrolimus (FK506) | Immunosuppressant (vernal conjunctivitis and perennial allergic conjunctivitis (eye drops)) | Phase 2 | |
| Prgraf | Tacrolimus (FK506) | Immunosuppressant (inflammatory bowel disease) | Phase 2 | new indication in preparation of Phase 2 in Europe |
| | (FK228) | Anticancer | | In preparation of Phase 2 in USA |

Changes from the previous announcement(November, 2000)

- In Japan, Prograf granular formulation was approved for liver and kidney transplantation in January 2001 and SNDA was filed for suppression of organ rejection in heart, lung, pancreas and small intestine transplant as well as myasthenia gravis in April 2001.
- Status of micafungin in Japan progressed to "to be filed" from "Phase 3".
- Myslee was launched in December 2000.
- Protopic for atopic dermatitis in USA was launched in February 2001.
- Status of Protopic for atopic dermatitis for pediatric use is in "Phase3" as a new indication.
- FK614 in USA progressed to "Phase2".